Table 2.

Characteristics of studies based on available raw data (n = 4) included in the meta-analysis of abstinence in patients with SSDs and comorbid SUDs.

Study (Author et al.)	Study design	N	Age [mean, years]	Sex [male %]	Ancestry	Diagnosis	Antipsychotic (s) exposure [mean dose]	Substance use outcomes/assessment of substance use	Type of substance assessed
Drake et al. (2000)	Prospective Cohort Study 3 years follow up	105	32.3	77.5	Predominantly European (96.7%)	Schz/SAD + SUD	1. Clozapine (n = 19) 2. FGA (n = 86)	Remission defined as AUS < 3 i.e., abstinence or use without impairment/TLBF, ASI, UDS, AUS, DUS, SATS	Alcohol
Green et al. (2003)	Retrospective Cohort Study 1 year follow-up	41	44.7	76	NS	Schz/SAD + SUD	1. Clozapine (n = 24) 439 mg/day 2. Risperidone (n = 8) 3.9 mg/day	Abstinence defined as cessation of all alcohol and cannabis use/Chart review as per clinician notes	Alcohol, cannabis
Brunette et al. (2006)	Prospective Cohort Study 1 year follow-up following “remission”	95	34	74.4	Predominantly European (96.4%)	Schz/SAD + SUD	1. Clozapine (n = 25) 484 mg/day 2. Other Aps (n = 70)	Remission defined as AUS/DUS < 3 i.e., abstinence or use without impairment /TLFB, ASI, UDS, AUS, DUS, SATS	Alcohol, cannabis, cocaine
Brunette et al. (2008)	Retrospective Cohort Study 6 to 12 months follow-up	86	40.3	79.1	NS	Schz/SAD + SUD	1. Clozapine 448.2 mg/day (n = 27) 2. Other Aps (n = 59) FGA = 35 405 mg/day CPZ equivalent Olanzapine = 24 18.2 mg/day	Abstinence defined as cessation of all alcohol use/Chart review as per clinician notes/ blood or urine test results, and recordings of Breathalyzer results	Alcohol

Aps: Antipsychotics; ASI: Addiction Severity Index; AUS: Alcohol Use Scale; BP: Bipolar Disorder; CPZ: chlorpromazine; DUS: Drug Use Scale; NS: Not Stated; FGA: First generation antipsychotics; SAD: Schizoaffective Disorder; SATS: Substance Abuse Treatment Scale; Schz: Schizophrenia; SUD: Substance Use Disorder; TLBF: Time-Line Follow-Back; UDS: Urine Drug Screen.